PTC-209|cas:315704-66-6|西域试剂

PTC-209,99.85%

产品编号：Bellancom-15888| CAS NO：315704-66-6| 分子式：C₁₇H₁₃Br₂N₅OS| 分子量：495.19

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15888	￥1023.00	杭州北京（现货）
Bellancom-15888	￥1500.00	杭州北京（现货）
Bellancom-15888	￥4900.00	杭州北京（现货）
Bellancom-15888	￥8400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PTC-209

产品介绍

PTC-209 是一种特定的 BMI-1 抑制剂，在 HEK293T 细胞系中的 IC₅₀ 为 0.5 μM。PTC-209 不可逆转地损害结直肠癌起始细胞 (CICs)。PTC-209 显示有效的抗骨髓瘤活性并损害肿瘤微环境。

生物活性

PTC-209 is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment.

体外研究

PTC-209 (0.01-10 µM; 24-72 hours) induces a concentration- and time-dependent decrease in the cellular viability of all cell lines tested.
PTC-209 (1-2.5 μM) inhibits STAT3 phosphorylation in A549 lung cancer cells and MDA-MB-231 breast cancer cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Lung (LNM35, A549 cells), breast (MDA-MB-231 and T47D cells), and colon (HT-29, HCT-116, and HCT8/S11 cells)
Concentration:	0.01-10 µM
Incubation Time:	24, 48, and 72 hour
Result:	Induced a concentration- and time-dependent decrease in the cellular viability of all cell lines tested.

体内研究
(In Vivo)

PTC-209 (60 mg/kg body weight; subcutaneously; once a day for 11 days) significantly reduces tumor volume.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor)
Dosage:	60 mg/kg body weight
Administration:	Subcutaneously; once a day for 11 days
Result:	Significantly reduced tumor volume

体内研究

PTC-209 (60 mg/kg body weight; subcutaneously; once a day for 11 days) significantly reduces tumor volume.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor)
Dosage:	60 mg/kg body weight
Administration:	Subcutaneously; once a day for 11 days
Result:	Significantly reduced tumor volume

体内研究

PTC-209 (60 mg/kg body weight; subcutaneously; once a day for 11 days) significantly reduces tumor volume.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor)
Dosage:	60 mg/kg body weight
Administration:	Subcutaneously; once a day for 11 days
Result:	Significantly reduced tumor volume

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 32 mg/mL (64.62 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0194 mL	10.0971 mL	20.1943 mL
5 mM	0.4039 mL	2.0194 mL	4.0389 mL
10 mM	0.2019 mL	1.0097 mL	2.0194 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.5 mg/mL (5.05 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (5.05 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液